Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brexpiprazole

FDA-approved product (tablet, oral), marketed as Brexpiprazole, Rexulti.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brexpiprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brexpiprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brexpiprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

    NCT01837797 · start 2013-04

    Registered record
    Registry ID
    NCT01837797
    Conditions
    Major Depressive Disorder
    Interventions
    Placebo; Brexpiprazole 1 mg; Brexpiprazole 3 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2013-04
    Completion
    2014-05
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionPlacebo; Brexpiprazole 1 mg; Brexpiprazole 3 mg
    PhasePhase 3
    Registry statusTerminated

  • Brexpiprazole in Patients With Acute Schizophrenia

    NCT01810380 · start 2013-03

    Registered record
    Registry ID
    NCT01810380
    Conditions
    Schizophrenia
    Interventions
    Placebo; Brexpiprazole; Quetiapine extended release
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03
    Completion
    2014-12
    Enrolment
    468

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPlacebo; Brexpiprazole; Quetiapine extended release
    PhasePhase 3
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

    NCT01668797 · start 2012-10

    Registered record
    Registry ID
    NCT01668797
    Conditions
    Acute Schizophrenia
    Interventions
    Brexpiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2015-02
    Enrolment
    524

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Schizophrenia
    InterventionBrexpiprazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

    NCT01670279 · start 2012-07

    Registered record
    Registry ID
    NCT01670279
    Conditions
    Major Depressive Disorder
    Interventions
    Brexpiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07
    Completion
    2013-05
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionBrexpiprazole; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

    NCT01360866 · start 2011-10

    Registered record
    Registry ID
    NCT01360866
    Conditions
    Depressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders; Mental Disorders
    Interventions
    OPC-34712; Escitalopram; Fluoxetine; Paroxetine CR; Sertraline; Duloxetine; Venlafaxine XR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-10
    Completion
    2017-05-18
    Enrolment
    2,944

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder; Depression; Depressive Disorder, Major; Mood Disorders +1 more
    InterventionOPC-34712; Escitalopram; Fluoxetine; Paroxetine CR +3 more
    PhasePhase 3
    Registry statusCompleted